Sandoz CEO warns of Trump's generic drug tariff threat
Sandoz CEO Richard Saynor warned that proposed U.S. tariffs on imported generic drugs would force manufacturers to either raise prices or stop supplying certain medicines. He emphasized that patients would ultimately bear the financial burden of these trade policies.
Why it matters
The warning highlights the potential impact of protectionist trade policies on healthcare affordability and supply chain stability.
American patients would ultimately bear the cost of President Donald Trump 's threatened tariffs on generic drugs, the CEO of Swiss pharmaceutical company Sandoz told CNBC, warning that manufacturers could be forced to raise prices or stop supplying some medicines.
"Patients pay the tariff," Sandoz CEO Richard Saynor said in an interview with CNBC during its Capital Markets Day.
"Any business is not going to systematically continue to supply a product at a material loss," he said on Tuesday. "So you either then have a choice of putting the price [up] or not supplying the product."
Trump said in July that imported generic medicines could face tariffs of 100% from 2028, rising to as much as 200% a year later, as his administration seeks to encourage drugmakers to shift pharmaceutical manufacturing to the United States.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in